Corcept Therapeutics Incorporated (CORT)
CORTNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$75.83
+0.8050 (+1.07%) today
Regular session, Nov 10, 10:14 AM ET
- Market cap
- $8.30bn
- P/E
- 59.7
- EPS, last 4 quarters
- $1.27
- Dividend yield
- –
- Day range
- $73.87 to $76.49
- 52-week range
- $28.66 to $126.38
- Average volume
- 1.32m
- Previous close
- $75.03
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $165.75, +118.6% from here
Earnings
next estimate $0.8700Next report
Dec 2025
-25.9%
Mar 2026
0.0%
Jun 2026
+1000.0%
Sep 2026
+48.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $202.13m | $164.90m | $256.15m | $340.47m |
| Gross profit | $199.58m | $162.02m | $252.09m | $335.86m |
| Operating income | $4.49m | -$49.60m | $41.30m | $114.72m |
| Net income | $24.29m | -$31.76m | $42.99m | $126.78m |
Last four quarters: revenue $963.65m, margin 16.8%, free cash flow $194.62m
News
8 latest- Corcept Therapeutics (CORT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y RevenuesZacks · 6 days ago
- Corcept Therapeutics Incorporated Reports Third Quarter 2026 Revenue of $340.5 millionFintel · 7 days ago
- Corcept Therapeutics Q3 Earnings Call HighlightsMarketBeat · 7 days ago
- Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass EstimatesZacks · 7 days ago
- Corcept Reports Positive Phase 2 BELLA Results For Lifyorl In Platinum-Resistant Ovarian Cancer RTTNews · Oct 26, 2026
- Notable Tuesday Option Activity: IREN, HTZ, CORTBNK Invest · Oct 20, 2026
- Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?Zacks · Oct 19, 2026
The company
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders. We have discovered more than 1,000 proprietary selective glucocorticoid receptor antagonists. Our development activities include advanced clinical trials in patients with hypercortisolism, a variety of solid tumors, ALS and liver disease. In 2012, we introduced Korlym, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous Cushing's syndrome. In March 2026, we introduced Lifyorli as a treatment for patients with platinum-resistant ovarian cancer. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist. We are headquartered in Redwood City, California. For more information, visit Corcept.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- corcept.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.